Sydney, Australia – October 27, 2016 In an industry first Novotech and Deloitte have teamed up to brief U.S. CFOs of early stage companies about Australian tax breaks for early phase clinical trials.

New research from Frost & Sullivan shows that Australia with its tax incentive program can be up to 60% more cost-effective to run trials than the USA.

The Frost & Sullivan report was released today at Outsourcing in Clinical Trials New England 2016 (September 7-8 2016, Boston).

Other relevant content